Use of more clinically relevant models of insulin resistance (such as defects in insulin receptor or post-receptor signaling components) should help to better understand the role of PGC-1α and its post-translational modification in the progression of insulin resistance-induced cardiomyopathy. The gene discussed is PPARGC1A; the disease is cardiomyopathy.